CTOs on the Move

Altru Health System

www.altru.org

 
Altru Health System is a community-owned, integrated system with an acute care hospital, a specialty hospital, more than a dozen clinics in Grand Forks and the region, a large home care network, and a congregate living facility. It employs more than 200 physicians and 4,000 staff and has an annual net operating revenue of more than $450 million. As the first member of the Mayo Clinic Care Network, Altru’s providers have access to clinically integrated tools extending Mayo Clinic’s knowledge and expertise to patients.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.altru.org
  • P.O. Box 6002
    Grand Forks, ND USA 58206
  • Phone: 701.780.5000

Executives

Name Title Contact Details

Similar Companies

Silverado Senior Living

Silverado Senior Living is a Redondo Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

eviti

eviti is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Central Health Management

Central Health Management is a healthcare staffing and recruiting agency that focuses on providing superior patient care by vetting top tier clinicians and offering a 24 hour staffing coverage model.

Sand Lake Medical Assoc

Sand Lake Medical Assoc is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.